GeneDx Securities Class Action Over Fabric Genomics
Analysis based on 274 articles · First reported Jun 04, 2026 · Last updated Aug 03, 2026
The securities class action and the underlying financial disclosures have severely impacted GeneDx Holdings Corporation's stock price, which fell 49.2% on May 5, 2026, erasing billions in shareholder value. The litigation and ongoing investigations create uncertainty for the company's future, potentially affecting its ability to raise capital and its reputation in the genomics market.
GeneDx Holdings Corporation Holdings Corp. (NASDAQ: WGS) is facing a securities class action lawsuit filed in the United States — United States District Court for the Northern District of California. The lawsuit alleges that GeneDx Holdings Corporation and certain executives made false and misleading statements regarding the acquisition of Fabric Genomics, an AI-driven genomic interpretation company. The class period is from April 16, 2025 to May 4, 2026. On May 4, 2026, GeneDx Holdings Corporation reported Q1 2026 financial results that missed revenue estimates for both exome and genome lines, disclosed a drop in adjusted gross margin from 74% to 69%, and recorded a $31.2 million impairment loss attributable to Fabric Genomics. The company also lowered its full-year 2026 revenue guidance to $475-$490 million from $540-$550 million. Following these disclosures, GeneDx Holdings Corporation's stock price fell 49.2% in a single session, from $67.93 to $34.51 per share. Multiple law firms, including Kahn Swick & Foti, Bronstein Gewirtz & Grossman, Pomerantz LLP, Hagens Berman, Rosen Law Firm, The Gross Law Firm, Faruqi & Faruqi, DJS Law Group, and The Schall Law Firm, have filed or are investigating claims. The lead plaintiff deadline is August 3, 2026. GeneDx Holdings Corporation also appointed Mark Gardner as new President following the stock collapse.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard